Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DA-2803 in Chronic Hepatitis B
NCT05957380Phase 4Completed
- Sponsor
- Dong-A ST
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Dong-A ST. Primary endpoint: Change in HBV DNA (log10 IU/mL) at 48 weeks. Started Mar 2023; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05957380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957380.